While much of the press covering the recently-passed “Inflation Reduction Act” talks about the long-term reduction to U. S. greenhouse gases, a huge benefit for drug costs (where the U. S. pays the highest in the world, and new drug launch prices have increased by 20% per year for the past 15 years) will be the ability for the U. S. to negotiate prices for Medicare recipients. Peter Maybarduk, Director of the Access to Medicine Program at Public Citizen talks about this huge consumer benefit.

Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate here